share_log

復星醫藥：截至2024年11月30日之股份發行人的證券變動月報表

FOSUN PHARMA: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 NOVEMBER 2024

HKEX ·  Dec 3, 2024 02:30

Summary by Moomoo AI

截至2024年11月30日，復星醫藥在香港聯交所的普通股H股進行了多次股份回購，總計回購862,500股，這些股份被持作庫存。回購活動分別於11月1日、25日、26日及27日進行，回購價格介於每股14.03至14.92港元之間。因為這些回購，已發行股份數量減少至545,606,500股，而庫存股份增加至6,334,000股。在法定/註冊股本方面，復星醫藥的H股和A股的法定股本保持不變，分別為551,940,500人民幣和2,119,385,965人民幣，總計2,671,326,465人民幣。公司確認所有回購活動均已獲董事會授權，並遵循相關法律及監管規定進行。未來，公司將繼續關注市場動態，適時調整股份結構以優化資本配置。
截至2024年11月30日，復星醫藥在香港聯交所的普通股H股進行了多次股份回購，總計回購862,500股，這些股份被持作庫存。回購活動分別於11月1日、25日、26日及27日進行，回購價格介於每股14.03至14.92港元之間。因為這些回購，已發行股份數量減少至545,606,500股，而庫存股份增加至6,334,000股。在法定/註冊股本方面，復星醫藥的H股和A股的法定股本保持不變，分別為551,940,500人民幣和2,119,385,965人民幣，總計2,671,326,465人民幣。公司確認所有回購活動均已獲董事會授權，並遵循相關法律及監管規定進行。未來，公司將繼續關注市場動態，適時調整股份結構以優化資本配置。
As of 30 November 2024, Fustar Pharmaceuticals had a number of share repurchases of ordinary H shares on the Hong Kong Stock Exchange for a total of 862,500 shares held in stock. The repurchase was conducted on November 1, 25, 26 and 27, respectively. The repurchase price ranges from HK$14.03 to HK$14.92 per share. As a result of these repurchases, the number of shares issued decreased to 545,606,500 shares and the number of shares in stock increased to 6,334,000 shares.In terms of regulated/registered share capital, the authorized share capital of Fustar Pharmaceutical's H shares and A shares remained unchanged at RMB551,940,500 and RMB2,119,385,965, respectively, for a total of RMB2,671,326,465. The Company confirms that all repurchases have been authorized by the Board of Directors and are conducted in compliance with relevant legal and regulatory requirements. In the future, the company will continue to focus on market dynamics and adjust its share structure in time to optimize capital allocation.
As of 30 November 2024, Fustar Pharmaceuticals had a number of share repurchases of ordinary H shares on the Hong Kong Stock Exchange for a total of 862,500 shares held in stock. The repurchase was conducted on November 1, 25, 26 and 27, respectively. The repurchase price ranges from HK$14.03 to HK$14.92 per share. As a result of these repurchases, the number of shares issued decreased to 545,606,500 shares and the number of shares in stock increased to 6,334,000 shares.In terms of regulated/registered share capital, the authorized share capital of Fustar Pharmaceutical's H shares and A shares remained unchanged at RMB551,940,500 and RMB2,119,385,965, respectively, for a total of RMB2,671,326,465. The Company confirms that all repurchases have been authorized by the Board of Directors and are conducted in compliance with relevant legal and regulatory requirements. In the future, the company will continue to focus on market dynamics and adjust its share structure in time to optimize capital allocation.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated